Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
In the last 90 days, Faeth Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Faeth Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $326.1K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$326.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Faeth Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Vousden Karen H | Director | – | Sep 15, 2026 | 1 |
| Craver Josiah | PAO | – | Jul 23, 2026 | 2 |
| Parikh Anand Kiran | President and CEO | 817,699 | Jul 23, 2026 | 4 |
| Stephenson Brian C | Chief Financial Officer | 46,688Indirect | Jul 1, 2026 | 3 |
| Ramasastry Saira | Director | – | Jun 16, 2026 | 1 |
| Hahn Stephen M. | Director | 44,763 | Jun 16, 2026 | 1 |
| Donenberg Phillip B. | Director | – | Jun 12, 2026 | 3 |
| Holmen Bob | Director | 25,598 | Jun 12, 2026 | 1 |
| Gerry Christopher | President & PEO | – | Jun 12, 2026 | 1 |
| Cambrian BioPharma Inc | 10% Owner | 130,142 | Jun 1, 2026 | 3 |
| Peyer James | 10% Owner, Other: See remarks below | 130,142 | Jun 1, 2026 | 3 |
| Englander Israel A | 10% Owner | 133,986Indirect | May 15, 2026 | 3 |
| Millennium Management LLC | 10% Owner | 133,986Indirect | May 15, 2026 | 3 |
| Millennium Group Management LLC | 10% Owner | 133,986Indirect | May 15, 2026 | 3 |
| Ics Opportunities II LLC | 10% Owner | 133,986Indirect | May 15, 2026 | 3 |
| Ricks Thomas G | Director | 8,932 | May 23, 2025 | 0 |
| Ringo William R | Director | 23,399 | May 23, 2025 | 0 |
| Humer Kristian | Director | 8,932 | May 23, 2025 | 0 |
| Celebi John | PRESIDENT AND CEO | 105,862 | Feb 26, 2025 | 0 |
| van der Horst Edward | CHIEF SCIENTIFIC OFFICER | 59,794 | Feb 26, 2025 | 0 |
| Krebs Stephanie | Chief Business Officer | – | Feb 14, 2025 | 0 |
| Vojta Deneen | Director | 8,932 | Jun 13, 2024 | 0 |
| English Jessie | Director | 8,932 | Jun 13, 2024 | 0 |
| Colgan Erin | CHIEF FINANCIAL OFFICER | 67,462 | Feb 16, 2024 | 0 |
| Gallagher Patrick Stephen | Chief Business Officer | 34,130 | Sep 11, 2023 | 0 |
| Broder Samuel | Director | 8,932 | Jul 12, 2023 | 0 |
| Presight Sensei Co-Invest Fund, L.P. | Other: See Explanation of Responses | 0Indirect | Jun 2, 2023 | 0 |
| Apeiron Investment Group Ltd. | 10% Owner | 0Indirect | Jun 2, 2023 | 0 |
| Angermayer Christian | 10% Owner | 0Indirect | Jun 2, 2023 | 0 |
| Presight Co-Invest Management, L.L.C. | Other: See Explanation of Responses | 0Indirect | Jun 2, 2023 | 0 |
| Pierce Robert Hamilton | Chief R&D Officer | 21,000 | Sep 1, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 18, 2022 (view filing) | Jan 13-14 | 5 days | Peyer JamesDirector, 10% Owner | PPurchase | +26.2K | $5.10 | +$133.4K | +0.5%4.98M after | 2 lotsDuplicate filing |
| Jan 18, 2022 (view filing) | Jan 13-14 | 5 days | Cambrian BioPharma Inc10% Owner | PPurchase | +26.2K | $5.10 | +$133.4K | +0.5%4.98M after | 2 lots |
| Jan 13, 2022 (view filing) | Jan 11-12 | 2 days | Peyer JamesDirector, 10% Owner | PPurchase | +20.0K | $5.20 | +$104.2K | +0.4%4.95M after | 2 lotsDuplicate filing |
| Jan 13, 2022 (view filing) | Jan 11-12 | 2 days | Cambrian BioPharma Inc10% Owner | PPurchase | +20.0K | $5.20 | +$104.2K | +0.4%4.95M after | 2 lots |
| Jan 11, 2022 (view filing) | Jan 10 | 1 day | Peyer JamesDirector, 10% Owner | PPurchase | +10.0K | $5.28 | +$52.8K | +0.2%4.93M after | Duplicate filing |
| Jan 11, 2022 (view filing) | Jan 10 | 1 day | Cambrian BioPharma Inc10% Owner | PPurchase | +10.0K | $5.28 | +$52.8K | +0.2%4.93M after | |
| Jan 3, 2022 (view filing)9:38 AM ET | Dec 30, 2021 | 4 days | Cambrian BioPharma Inc10% Owner | PPurchase | +1.13K | $4.85 | +$5.47K | 0.0%4.92M after | Duplicate filing |
| Jan 3, 2022 (view filing) | Dec 30, 2021 | 4 days | Peyer JamesDirector, 10% Owner | PPurchase | +1.13K | $4.85 | +$5.47K | 0.0%4.92M after | |
| Dec 30, 2021 (view filing) | Dec 29 | 1 day | Peyer JamesDirector, 10% Owner | PPurchase | +69.0K | $4.98 | +$343.6K | +1.4%4.92M after | Duplicate filing |
| Dec 30, 2021 (view filing) | Dec 29 | 1 day | Cambrian BioPharma Inc10% Owner | PPurchase | +69.0K | $4.98 | +$343.6K | +1.4%4.92M after | |
| Dec 29, 2021 (view filing) | Dec 28 | 1 day | Peyer JamesDirector, 10% Owner | PPurchase | +11.3K | $5.28 | +$59.6K | +0.2%4.85M after | Duplicate filing |
| Dec 29, 2021 (view filing) | Dec 28 | 1 day | Cambrian BioPharma Inc10% Owner | PPurchase | +11.3K | $5.28 | +$59.6K | +0.2%4.85M after | |
| Dec 27, 2021 (view filing) | Dec 27 | Same day | Peyer JamesDirector, 10% Owner | PPurchase | +3.71K | $5.30 | +$19.7K | +0.1%4.84M after | Duplicate filing |
| Dec 27, 2021 (view filing) | Dec 27 | Same day | Cambrian BioPharma Inc10% Owner | PPurchase | +3.71K | $5.30 | +$19.7K | +0.1%4.84M after | |
| Dec 23, 2021 (view filing) | Dec 23 | Same day | Peyer JamesDirector, 10% Owner | PPurchase | +11.0K | $5.27 | +$58.0K | +0.2%4.83M after | Duplicate filing |
| Dec 23, 2021 (view filing) | Dec 23 | Same day | Cambrian BioPharma Inc10% Owner | PPurchase | +11.0K | $5.27 | +$58.0K | +0.2%4.83M after | |
| Dec 21, 2021 (view filing) | Dec 17 | 4 days | Peyer JamesDirector, 10% Owner | PPurchase | +117 | $5.29 | +$618.93 | 0.0%4.82M after | Duplicate filing |
| Dec 21, 2021 (view filing) | Dec 17 | 4 days | Cambrian BioPharma Inc10% Owner | PPurchase | +117 | $5.29 | +$618.93 | 0.0%4.82M after | |
| Dec 20, 2021 (view filing) | Dec 16 | 4 days | Cambrian BioPharma Inc10% Owner | PPurchase | +10.9K | $5.25 | +$57.4K | +0.2%4.82M after | Duplicate filing |
| Dec 20, 2021 (view filing) | Dec 16 | 4 days | Peyer JamesDirector, 10% Owner | PPurchase | +10.9K | $5.25 | +$57.4K | +0.2%4.82M after | |
| Dec 13, 2021 (view filing) | Dec 9-10 | 4 days | Ricks Thomas GDirector | PPurchase | +40.0K | $6.24 | +$249.6K | +13.3%341.8K after | 2 lots |
| Aug 12, 2021 (view filing) | Aug 11 | 1 day | Pierce Robert HamiltonChief Scientific Officer | SSale | −16.0K | $7.34 | −$117.7K | −100.0%0 after | |
| Aug 10, 2021 (view filing) | Aug 6-10 | 4 days | Pierce Robert HamiltonChief Scientific Officer | SSale | −79.8K | $7.12 | −$568.3K | −83.3%16.0K after | 3 lots |